Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy.
about
Biologics in organ transplantationMeasles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy.Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma.Human viruses and cancer.A genome-wide integrative genomic study localizes genetic factors influencing antibodies against Epstein-Barr virus nuclear antigen 1 (EBNA-1).EBV-associated lymphomas in adultsEpstein-Barr virus-positive T/NK-cell lymphoproliferative disordersEBNA3C augments Pim-1 mediated phosphorylation and degradation of p21 to promote B-cell proliferationThe Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac.Posttransplant Lymphoproliferative Disorder of the Thorax: CT and FDG-PET Features in a Single Tertiary Referral CenterVariable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients.Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation.Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.Graft rejection in pediatric liver transplant patients with Epstein-Barr viremia and post-transplant lymphoproliferative disease.Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens.Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.Multiple infections and cancer: implications in epidemiology.Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management.Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation.A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors.Posttransplant Lymphoproliferative Disorders in Neuronal Xenotransplanted Macaques.Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.The Epstein-Barr virus microRNA BART11-5p targets the early B-cell transcription factor EBF1.A Solid Mass in the Chest Wall.First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.Influence of Posttransplant Lymphoproliferative Disorder on Survival in Children After Heart Transplantation.Whole blood EBV-DNA: A surrogate for immune dysfunction in aggressive lymphoma?Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations.Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival.Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation.Effective control of Epstein-Barr virus infection following pediatric liver transplantation by monitoring of viral DNA load and lymphocyte surface markers.Posttransplant Lymphoproliferative Disorder Isolated to the Adrenal Gland in a Liver Transplant Patient.Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes.Impact of the posttransplant lymphoproliferative disorder subtype on survival.Pharmacodynamic monitoring by residual NFAT-regulated gene expression in stable pediatric liver transplant recipients.
P2860
Q26829578-FD81A126-8EFB-47E4-811A-33D57FC6340FQ30557338-C6F95DD7-E516-4CBE-BDEE-0911CB4F2DD5Q31116522-8FA9A11D-5136-4D0D-80C1-509A4A8E40E7Q34423461-130C7898-14C1-4026-B3AF-1963A45F111BQ34550781-01AD39BB-9FEE-4315-9621-57212544F5D7Q34636601-D4F7376E-E04A-4338-BFC7-8E921340F082Q35040638-B561F21F-DB7B-45FA-897C-45DF865F4329Q35224422-B34D1351-42CE-41AB-8A77-EDE7ED6E4F08Q35903344-D16E366A-1176-472A-9F7C-BBB791A6AF83Q36194638-B3FEAF11-A351-4EE0-BE14-74E30FCE1E5EQ36537637-B89E4958-F25E-497A-8850-AD1A6A6314B1Q37145738-985AFB8D-251A-416A-9A30-766F9B3870F5Q37975458-CC1B254B-7D15-4D78-8227-42D4235A2F36Q38007190-93A6E9B3-1906-46DA-A645-830C907E0EC7Q38032320-427D2C74-11CB-41DF-8855-EE4140052904Q38061056-90F50D0B-336D-4245-B514-E0F3D2B1463FQ38108302-D6AE4991-D2E4-4C23-A535-57F6BB01397DQ38112050-74DB40B6-696B-49F6-97F1-EAED8FE80435Q38126931-B67E8CB2-BCD7-4A5B-B39E-82547A6C362BQ38833567-8B294999-594C-49A0-B761-DAAF3B6B6DABQ38937601-E27B36FD-11D6-4AA6-9CA8-232A6F9AE9D9Q38965273-FBD54368-A6FE-4D8C-8D5C-C05AC45084C6Q39330801-16AED65B-05F2-4E09-BE64-851A22215A7AQ39367196-37D3C6AD-A6A3-476D-981C-4F0B43B67F9EQ40134553-75FE06B6-36BD-4456-AB85-C564BC26D38EQ40609933-EEB41CAD-1041-4055-9539-41892BE658E7Q40656850-02826282-1168-43CC-BCF2-7820E6BAA8C2Q40723071-9F9028FE-8E59-421F-83B3-F77826B07CA5Q41027997-883D1C49-B7C0-42C3-886C-BB9C91026336Q41189728-F3F384E8-8BE0-49CD-8A43-0A48F5012562Q41573231-29581E4A-A4D3-45E1-AA28-532864336AADQ42051829-01450FC2-70B9-49D9-B2DC-E7FFB178AA1DQ42229199-DFB8DF1D-92BE-4584-9A4C-7D471EDC1755Q42244554-8F159AD6-02E8-464C-86FC-AE7F4104EC28Q42272334-2AED25E8-DEA6-435C-92B0-C34765F7B4EFQ43520891-56DAB0E7-FB2C-4622-BFDE-917ED7221B11Q49452716-BA2473B6-C84F-4D55-B8DD-7B7913406E80Q49798727-B88AADDB-0650-4D94-A1F6-D11199B72C06Q51734713-DAEE6C3A-E938-4622-B15D-9CCCDC161863Q54322567-79A02576-1ACC-4AED-A905-E5B2A0FA6061
P2860
Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Epstein-Barr Virus-related pos ...... insights for targeted therapy.
@ast
Epstein-Barr Virus-related pos ...... insights for targeted therapy.
@en
Epstein-Barr Virus-related pos ...... insights for targeted therapy.
@nl
type
label
Epstein-Barr Virus-related pos ...... insights for targeted therapy.
@ast
Epstein-Barr Virus-related pos ...... insights for targeted therapy.
@en
Epstein-Barr Virus-related pos ...... insights for targeted therapy.
@nl
prefLabel
Epstein-Barr Virus-related pos ...... insights for targeted therapy.
@ast
Epstein-Barr Virus-related pos ...... insights for targeted therapy.
@en
Epstein-Barr Virus-related pos ...... insights for targeted therapy.
@nl
P2860
P1476
Epstein-Barr Virus-related pos ...... insights for targeted therapy
@en
P2093
J P Nourse
M K Gandhi
P2860
P304
P356
10.1111/J.1600-6143.2011.03499.X
P407
P577
2011-05-01T00:00:00Z